AR128315A1 - Profármacos y sus usos - Google Patents

Profármacos y sus usos

Info

Publication number
AR128315A1
AR128315A1 ARP230100137A ARP230100137A AR128315A1 AR 128315 A1 AR128315 A1 AR 128315A1 AR P230100137 A ARP230100137 A AR P230100137A AR P230100137 A ARP230100137 A AR P230100137A AR 128315 A1 AR128315 A1 AR 128315A1
Authority
AR
Argentina
Prior art keywords
glp
gip receptor
compound according
coagonist
receptor coagonist
Prior art date
Application number
ARP230100137A
Other languages
English (en)
Spanish (es)
Inventor
Patrick James Knerr
Brian Patrick Finan
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR128315A1 publication Critical patent/AR128315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP230100137A 2022-01-20 2023-01-20 Profármacos y sus usos AR128315A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263301311P 2022-01-20 2022-01-20
EP22154309 2022-01-31

Publications (1)

Publication Number Publication Date
AR128315A1 true AR128315A1 (es) 2024-04-17

Family

ID=85036152

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100137A AR128315A1 (es) 2022-01-20 2023-01-20 Profármacos y sus usos

Country Status (7)

Country Link
US (2) US11840560B2 (enExample)
EP (1) EP4466069A1 (enExample)
JP (2) JP7434616B2 (enExample)
KR (2) KR102704620B1 (enExample)
AR (1) AR128315A1 (enExample)
TW (1) TW202330584A (enExample)
WO (1) WO2023139187A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250039299A (ko) 2023-09-11 2025-03-20 노보 노르디스크 에이/에스 항-il-6 도메인 항체
TWI926512B (zh) * 2023-11-30 2026-05-21 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑
WO2025252197A1 (zh) * 2024-06-07 2025-12-11 江苏恒瑞医药股份有限公司 药物组合物
WO2026052063A1 (en) * 2024-09-06 2026-03-12 Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. Glp-1 polypeptide prodrugs and uses thereof
KR102991397B1 (ko) * 2024-11-29 2026-07-21 노보 노르디스크 에이/에스 Glp-1, gip, 및 아밀린 수용체의 삼중작용제 및 이의 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
JP2012512898A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション ジペプチド結合薬用剤
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
KR20130083843A (ko) 2010-06-24 2013-07-23 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 디펩티드 연결된 약제
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
RU2013133803A (ru) 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
CA2872314C (en) 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
SI2864350T1 (en) 2012-06-21 2018-08-31 Indiana University Research And Technology Corporation GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
US20160058881A1 (en) 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
DK3004155T3 (da) 2013-05-28 2022-01-03 Takeda Pharmaceuticals Co Peptidforbindelse
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
WO2015035419A1 (en) 2013-09-09 2015-03-12 Hoffmann-La Roche Inc. Dosages of gip/glp-1 co-agonist peptides for human administration
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
WO2016077220A1 (en) 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
JP2018012644A (ja) 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
AR103242A1 (es) 2015-01-09 2017-04-26 Lilly Co Eli Compuestos co-agonistas de gip y glp-1
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
US20170112897A1 (en) 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
EP3467106B1 (en) 2016-05-24 2025-07-09 Takeda Pharmaceutical Company Limited Peptide compound
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
PE20210473A1 (es) 2018-05-04 2021-03-08 Novo Nordisk As Derivados de gip y usos de estos
AU2019309798A1 (en) 2018-07-23 2021-02-11 Eli Lilly And Company Method of using a GIP/GLP1 co-agonist for diabetes
KR20250044806A (ko) 2018-07-23 2025-04-01 일라이 릴리 앤드 캄파니 요법을 위한 gip/glp1 공효능제 사용 방법
ES3068975T3 (en) 2018-07-23 2026-06-03 Lilly Co Eli Gip/glp1 co-agonist compounds
AU2020256648B2 (en) 2019-04-11 2026-01-15 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Multi-receptor agonist and medical use thereof
CN110642935A (zh) 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
CN110684082B (zh) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
AU2021312323A1 (en) 2020-07-22 2023-02-02 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery

Also Published As

Publication number Publication date
KR20230112568A (ko) 2023-07-27
EP4466069A1 (en) 2024-11-27
JP2023106355A (ja) 2023-08-01
TW202330584A (zh) 2023-08-01
JP7434616B2 (ja) 2024-02-20
KR20230159805A (ko) 2023-11-22
US20230227521A1 (en) 2023-07-20
US20240083965A1 (en) 2024-03-14
US11840560B2 (en) 2023-12-12
WO2023139187A1 (en) 2023-07-27
JP2024015148A (ja) 2024-02-01
KR102704620B1 (ko) 2024-09-12

Similar Documents

Publication Publication Date Title
AR074811A1 (es) Profarmaco de peptido de la superfamilia de glucagon basados en amida
CO2022015930A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
AR082995A1 (es) Profarmacos que comprenden un conjugado de conector de exendina
CL2022003041A1 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
DOP2025000087A (es) Compuestos tricíclicos y sus usos
PY2019955A (es) Inhibidores de inflamasoma nlrp3
CO6491083A2 (es) Profarmacos que comprenden un conugado de insulina-conector
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
UY33044A (es) Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos
AR065135A1 (es) Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
UY31351A1 (es) (ciclopropilfenil)feniloxamidas, procedimiento para su preparación y su uso como medicamentos
CR20110617A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
AR077252A1 (es) Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
BR112015005972A2 (pt) derivados do tipo amida de ácido benzoimidazol-carboxílico como moduladores do receptor apj
CL2008002787A1 (es) Compuestos derivados de piperidina, que presentan actividad moduladora sobre la actividad del receptor gpr 119; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades tales como diabetes tipo 1 y 2, hiperllpidemia, enfermedad coronaria, obesidad y disfuncion erectil.
ECSP109962A (es) Nuevos compuestos antimicrobianos, su síntesis y su uso para el tratamiento de infecciones en mamíferos
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
UY29316A1 (es) Miméticos de glucocorticoides, métodos para prepararlos, composiciones farmacéuticas, y usos de los mismos.
PA8651001A1 (es) Compuestos quimicos
AR072072A1 (es) Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CR9722A (es) Derivados de benzilpiperazina y su uso medico

Legal Events

Date Code Title Description
FB Suspension of granting procedure